| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 11/25/1999 | WO1999059593A1 Combination therapy for treatment of depression |
| 11/25/1999 | WO1999059585A1 Compositions for the treatment of hiv and other viral infections |
| 11/25/1999 | WO1999059584A1 Combination of phentolamine and cyclic gmp phosphodiesterase inhibitors for the treatment of sexual dysfunction |
| 11/25/1999 | WO1999059583A1 Method for treating or preventing chronic nonbacterial prostatitis and prostatodynia |
| 11/25/1999 | WO1999059577A1 Topical application of muscarinic analgesic drugs such as neostigmine |
| 11/25/1999 | WO1999059571A1 Use of amyloid inhibitors for modulating neuronal cell death |
| 11/25/1999 | WO1999059565A1 Novel compositions |
| 11/25/1999 | WO1999059553A1 Effervescent preparations |
| 11/25/1999 | WO1999059549A1 Biodegradable sustained-release alginate gels |
| 11/25/1999 | WO1999059548A1 Controlled drug delivery system using the conjugation of drug to biodegradable polyester |
| 11/25/1999 | WO1999059523A2 Topical pharmaceutical compositions useful for the treatment of cutaneous or circulatory pathologies on inflammatory, immune, proliferative or degenerative basis |
| 11/25/1999 | WO1999049844A3 Method for producing transdermal therapeutic systems by using basic alkali metal salts for converting active agent salts into free bases |
| 11/25/1999 | WO1999048523A3 Antagonists of the inflammatory mediator oncostatin m (osm) |
| 11/25/1999 | WO1999048484A3 Use of cabergoline in the treatment of restless legs syndrome |
| 11/25/1999 | WO1999044595A3 Pharmaceutical compositions for ulcer |
| 11/25/1999 | WO1999043832A3 Human proteinase molecules |
| 11/25/1999 | WO1999042834A3 Treating cancer |
| 11/25/1999 | WO1999039740A9 Sensitizing cells to compounds using lipid-mediated gene and compound delivery |
| 11/25/1999 | WO1999038976A3 Human growth factor homologs |
| 11/25/1999 | WO1999031969A3 Transgenic animal model for degenerative diseases of cartilage |
| 11/25/1999 | WO1998041226A9 Pharmaceutical combined preparations containing erythropoietin and iron preparations |
| 11/25/1999 | WO1998018500A8 Improvements in or relating to diagnostic/therapeutic agents |
| 11/25/1999 | CA2333310A1 Use of tricyclic antidepressants for local analgesia |
| 11/25/1999 | CA2333203A1 Methods for modulating neuronal cell death |
| 11/25/1999 | CA2332774A1 Method for the treatment of gastroesophageal reflux disease |
| 11/25/1999 | CA2332771A1 Ionophore containing composition for modulating amyloidosis |
| 11/25/1999 | CA2332507A1 Angiostatin receptor |
| 11/25/1999 | CA2332331A1 Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases |
| 11/25/1999 | CA2332253A1 Combination therapy for treatment of depression |
| 11/25/1999 | CA2330471A1 Compositions and methods for prevention and treatment of uncontrolled formation of intravascular fibrin clots |
| 11/25/1999 | CA2329916A1 Potassium channel agonists |
| 11/25/1999 | CA2329877A1 Compositions for the treatment of hiv and other viral infections |
| 11/25/1999 | CA2328893A1 Vegf activity inhibitors |
| 11/25/1999 | CA2328603A1 Novel compositions comprising interleukin-18 and a chemotherapeutic agent |
| 11/25/1999 | CA2328529A1 Immunoregulator from a human chorionic gonadotropin preparation |
| 11/25/1999 | CA2328509A1 Methods and use of compositions comprising tnf-rii(p75) agonists for treating asthma and other allergic conditions |
| 11/25/1999 | CA2328496A1 Il-17 homologous polypeptides and therapeutic uses thereof |
| 11/25/1999 | CA2328489A1 Secreted proteins and polynucleotides encoding them |
| 11/25/1999 | CA2327585A1 Use of a cox-2 inhibitor and a nk-1 receptor antagonist for treating inflammation |
| 11/24/1999 | EP0958835A1 Preventive/remedy for frequent urination and urinary incontinence |
| 11/24/1999 | EP0958833A1 Methods and means for preventing or treating inflammation |
| 11/24/1999 | EP0958825A1 Synergistic composition of a non-digestible carbohydrate and an anti-cancer drug for use in the treatment of cancer |
| 11/24/1999 | EP0958824A2 Olanzapine (zyprexa) in combination with fluoxetine (prozac), lithium or anticonvulsant for therapy of refractory depression |
| 11/24/1999 | EP0958371A2 Cytopathic viruses for therapy and prophylaxis of neoplasia |
| 11/24/1999 | EP0958366A1 Human chemokine beta-13 |
| 11/24/1999 | EP0958363A1 Human regulator of g-protein signaling - (hrgs) |
| 11/24/1999 | EP0958361A1 Rath genes and polypeptides and methods for the treatment and diagnosis of immune disorders |
| 11/24/1999 | EP0958305A2 Inhibitions of the interaction between p53 and mdm2 |
| 11/24/1999 | EP0958304A1 Nucleotide sequence encoding the cd33-like protein |
| 11/24/1999 | EP0957936A1 Formulations of recombinant papillomavirus vaccines |
| 11/24/1999 | EP0957932A2 A method and composition for enabling passage through the blood-brain barrier |
| 11/24/1999 | EP0957929A1 Vascular endothelial growth factor (vegf) nucleic acid ligand complexes |
| 11/24/1999 | EP0957919A1 Analgesic composition for treatment of migraine headaches |
| 11/24/1999 | EP0957917A1 Vitronectin receptor antagonists |
| 11/24/1999 | EP0957914A1 Formulation of 5-ht agonists |
| 11/24/1999 | EP0957910A2 Method of regulating the female reproductive system through angiogenesis inhibitors |
| 11/24/1999 | EP0957909A1 Use of nitric oxid synthase inhibitors for the treatment of diabetes |
| 11/24/1999 | EP0957908A1 Fibrinogen receptor antagonists |
| 11/24/1999 | EP0957901A1 Pharmaceutical preparations of glutathione and methods of administration thereof |
| 11/24/1999 | EP0957900A1 Compositions and methods for topical application of therapeutic agents |
| 11/24/1999 | EP0808165A4 Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by exogenous and endogenous opioid agonists |
| 11/24/1999 | CN1046635C Composition and mether using nitrooxides to avoid oxygen toxicity |
| 11/23/1999 | US5990241 Polyoxypropylene/polyoxyethylene copolymers with improved biological activity |
| 11/23/1999 | US5990159 Pharmaceutical formulations comprising a selective serotonin reuptake inhibitors and a 5ht4 receptor antagonists; reduction of gastrointestinal side effects |
| 11/23/1999 | US5990148 Side effect reductions; antiarthritic agents; nonsteroidal antiinflammatory agents |
| 11/23/1999 | US5990141 Administering 5-methyl-isoxazole-4-carboxylic acid-n-(4-trifluoromethyl)anilide or 2-cyano-3-hydroxy-n-(4-trifluoro-methyl)phenyl-2-butenamide; antitumor,-carcinogenic and proliferative agents; kinase inhibitors |
| 11/23/1999 | US5990128 Administering an antagonist that binds to a human alpha-1c adrenergic receptor with a binding affinity at least 691-fold higher than the binding affinity with which the antagonist binds to a human alpha-1b adrenergic receptor |
| 11/23/1999 | US5990111 Aldose reductase inhibition in preventing or reversing diabetic cardiomyopathy |
| 11/23/1999 | US5990103 Treating psoriasis by topical adminstration of pentoxifylline and diltiazem to a patient; a combination of a compound having a phosphodiesterase-inhibiting action, and a compound which reduces the intracellular calcium content |
| 11/23/1999 | US5990099 Treating glc1a glaucoma by administering an angiostatic steroid of given formula |
| 11/23/1999 | US5990095 Use of hyaluronic acid and forms to prevent arterial restenosis |
| 11/23/1999 | US5990083 Composition for reducing cu/zn superoxide dismutase-1 enzyme degradation by inhibiting multicatalytic protease; treating muscle wasting diseases associated with low superoxide dismutase-1 enzyme activity |
| 11/23/1999 | US5989895 β-(1-3)-glucanosyltransferase, oligonucleotides encoding this enzyme, and molecules having effects on this enzyme |
| 11/23/1999 | US5989884 Polypeptides of the histidyl transfer rna synthetase family; for screening of antibiotics, bactericides, and bacteristats for treatment and prevention of clamydial infections; diagnosis |
| 11/23/1999 | US5989863 Human ankyrin family protein |
| 11/23/1999 | US5989834 Contacting nonneuronal cells transfected with vector; gene expression |
| 11/23/1999 | US5989832 Method for screening for non-tetracycline efflux pump inhibitors |
| 11/23/1999 | US5989822 Diagnosis and treatment of cancer, neurodegenerative and autoimmune diseases; gene expression |
| 11/23/1999 | US5989804 E6 binding proteins |
| 11/23/1999 | US5989803 Method for treating a subject suffering from a condition associated with an extracellular zinc sphingomyelinase |
| 11/23/1999 | US5989539 Compounds and compositions for delivering active agents |
| 11/23/1999 | US5989522 Anti-mycotic drug and ethyl cellulose to provide sustained release |
| 11/23/1999 | US5989463 Methods for fabricating polymer-based controlled release devices |
| 11/23/1999 | CA1340825C Hyaluronic acid fraction for use as a drug delivery system for medicaments |
| 11/22/1999 | CA2272639A1 Improved drug formulations |
| 11/19/1999 | CA2237915A1 Osteoporosis treatment |
| 11/18/1999 | WO1999058968A1 Diagnosis of predisposition to epilepsy and monitoring of antiepileptic treatment |
| 11/18/1999 | WO1999058947A2 Modulation of molecular interaction sites on rna and other biomolecules |
| 11/18/1999 | WO1999058692A2 Human apoptosis associated proteins |
| 11/18/1999 | WO1999058678A2 Antibodies to dendritic cells and human dendritic cell populations and uses thereof |
| 11/18/1999 | WO1999058573A1 Diagnosis and treatment of hepatic disorders |
| 11/18/1999 | WO1999058558A2 Cell signaling proteins |
| 11/18/1999 | WO1999058505A2 Combinations of protein farnesyltransferase and hmg coa reductase inhibitors and their use to treat cancer |
| 11/18/1999 | WO1999058162A2 Pharmaceuticals for the imaging of angiogenic disorders |
| 11/18/1999 | WO1999058155A1 Formulations useful for modulating expression of exogenous genes in mammalian systems, and products related thereto |
| 11/18/1999 | WO1999058139A2 Methods for detecting and inhibiting angiogenesis |
| 11/18/1999 | WO1999058132A1 Use of a farnesyl transferase inhibitor in the manufacture of a medicament for local administration to the vascular wall in the prevention of restenosis |
| 11/18/1999 | WO1999058126A1 Use of neomycin for treating angiogenesis-related diseases |
| 11/18/1999 | WO1999058118A2 METHODS FOR REGULATING HEMATOPOIESIS USING CpG-OLIGONUCLEOTIDES |
| 11/18/1999 | WO1999058110A1 Mucoadhesive compositions for administration of biologically active agents to animal tissue |